RAD51 and XRCC3 polymorphisms: Impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia

Leukemia Research

Volumn 35, Issue 8, 2011, Pages 1020-1026

  Liu, Liang ^a   Yang, Lin ^a   Mi, Yingchang ^a   Wang, Jianxiang ^a   Li, Jianyong ^b   Zhang, Yue ^a   Ma, Xiaotang ^a   Qin, Tiejun ^a   Xu, Zefeng ^a   Xiao, Zhijian ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; DNA repair; Outcome; Polymorphism; Susceptibility

Indexed keywords

CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 16; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RAD51 GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; VOLUNTEER; XRCC3 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHROMOSOME INVERSION; CHROMOSOMES, HUMAN, PAIR 16; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RAD51 RECOMBINASE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960210767     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.014     Document Type: Article

References (38)

1. Kundu M., Liu P.P. Function of the inv(16) fusion gene CBFB-MYH11. Curr Opin Hematol 2001, 8:201-205.
2. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998, 92:2322-2333.
3. Byrd J.C., Mrózek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
4. Mrozek K., Heinonen K., de la Chapelle A., Bloomfield C.D. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997, 24:17-31.
5. Delaunay J., Vey N., Leblanc T., et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003, 102:462-469.
6. Razzouk B.I., Raimondi S.C., Srivastava D.K., et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia 2001, 15:1326-1330.
7. Xiao Z., Greaves M.F., Buffler P., et al. Molecular characterization of genomic AML1-ETO fusion in childhood leukemia. Leukemia 2001, 15:1906-1913.
8. Zhang Y., Strissel P., Strick R., et al. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A 2002, 99:3070-3075.
9. Hasan S.K., Mays A.N., Ottone T., et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008, 112:3383-3390.
10. Reiter A., Saussele S., Grimwade D., et al. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer 2003, 36:175-188.
11. van der Reijden B.A., Dauwerse H.G., Giles R.H., et al. Genomic acute myeloid leukemia-associated inv(16)(p13; q22) breakpoints are tightly clustered. Oncogene 1999, 18:543-550.
12. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002, 2:351-360.
13. Conway A.B., Lynch T.W., Zhang Y., et al. Crystal structure of a Rad51 filament. Nat Struct Mol Biol 2004, 11:791-796.
14. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
15. Tsuzuki T., Fujii Y., Sakumi K., et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci U S A 1996, 93:6236-6240.
16. Lim D.S., Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 1996, 16:7133-7143.
17. Sonoda E., Sasaki M.S., Buerstedde J.M., et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 1998, 17:598-608.
18. Vispe S., Cazaux C., Lesca C., Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998, 26:2859-2864.
19. Kim P.M., Allen C., Wagener B.M., Shen Z., Nickoloff J.A. Overexpression of human RAD51 and RAD52 reduces double-strand break-induced homologous recombination in mammalian cells. Nucleic Acids Res 2001, 29:4352-4360.
20. Richardson C., Stark J.M., Ommundsen M., Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004, 23:546-553.
21. Shen M.R., Jones I.M., Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998, 58:604-608.
22. Au W.W., Salama S.A., Sierra-Torres C.H. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003, 111:1843-1850.
23. Savas S., Kim D.Y., Ahmad M.F., Shariff M., Ozcelik H. Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004, 13:801-807.
24. Lindh A.R., Rafii S., Schultz N., Cox A., Helleday T. Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility. Hum Mol Genet 2006, 15:1217-1224.
25. Voso M.T., Fabiani E., D'Alo' F., et al. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol 2007, 18:1523-1528.
26. Seedhouse C., Faulkner R., Ashraf N., Das-gupta E., Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004, 10:2675-2680.
27. Bhatla D., Gerbing R.B., Alonzo T.A., et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia 2008, 22:265-272.
28. Borthakur G., Estey A.E. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep 2007, 9:373-377.
29. Yang L., Zhang M.R., Zhang Y., Xu S.C., Liu X.P., Xiao Z.J. Relationship of RAD51-G135C and XRCC3-C241T gene polymorphisms with acute myeloid leukemia, myelodysplastic syndromes and karyotype abnormalities. Zhong hua Xue Ye Xue Za Zhi 2006, 27:727-731.
30. Liu L., Yang L., Zhang Y., Xu Z.F., Yu M.H., Wang J.X., et al. Polymorphisms of RAD51(G135C) and XRCC3(C241T) genes and correlations thereof with prognosis and clinical outcomes of acute myeloid leukemia. Zhonghua Yi Xue Za Zhi 2008, 88:378-382.
31. Xiao Z., Xue H., Li R., Zhang L., Yu M., Hao Y. The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia. Am J Hematol 2008, 83:203-205.
32. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
33. Hilsenbeck S.G., Clark G.M. Practical P-value adjustment for optimally selected cut-points. Stat Med 1996, 15:103-112.
34. Valent P., Horny H.P., Bennett J.M., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
35. Marcucci G., Mrózek K., Ruppert A.S., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B Study. J Clin Oncol 2005, 23:5705-5717.
36. Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004, 22:3741-3750.
37. Boissel N., Leroy H., Brethon B., et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20:965-970.
38. Kuptsova N., Kopecky K.J., Godwin J., et al. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 2007, 109:3936-3944.